Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
But with the right trials, safety profiling, and delivery innovation, it just might be
Clinical Safety and Reproductive Considerations Pregnancy and Conception GLP-1 RAs are not recommended during pregnancy due to insufficient safety data
GHK-Cu Dosage Chart The main rule: stay consistent and use the product the way it was designed to be used
It doesnt cure aging (nothing does), but it appears to modulate several pathways that otherwise accelerate it
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Fetal programming of neuropsychiatric disorders
US$ 27.68
US$ 20.68
US$ 23.60
US$ 25.04
US$ 23.84
US$ 20.21
